Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 13/20 | 0.48 |
| ▸ | THRA | P10827 | 12/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1531388 | 0.82 | GABRB3 (0.36) | THRBTHRA | |
| SCHEMBL1531172 | 0.81 | THRA (0.39) | THRBTHRA | |
| SCHEMBL13325365 | 0.78 | THRA (0.35) | THRBTHRA | |
| SCHEMBL1531076 | 0.77 | DHODH (0.39) | THRBTHRASMN1; SMN2 | |
| SCHEMBL13387116 | 0.75 | THRB (0.38) | THRBTHRA | |
| SCHEMBL1531374 | 0.75 | MAPK1 (0.48) | THRBTHRASMN1; SMN2 | |
| SCHEMBL1531133 | 0.75 | GABRA2 (0.36) | THRBTHRA | |
| SCHEMBL1531105 | 0.71 | THRA (0.41) | THRBTHRA | |
| SCHEMBL1531412 | 0.70 | ALDH1A1 (0.42) | THRBTHRASMN1; SMN2 | |
| SCHEMBL1531138 | 0.70 | DHODH (0.36) | THRBTHRASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362852-B1 | PYRAZOLE DERIVATIVE, INTERMEDIATE THEREFOR, PROCESSES FOR PRODUCING THESE, AND HERBICIDE CONTAINING THESE AS ACTIVE INGREDIENT | SAGAMI CHEM RES (JP) | 2011-04-06 | — | — | EP | disclosed |
| EP-2292606-A1 | Pyrazole derivative, its intermediate, and herbicide containing the same as active ingredient | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-20100152443-A1 | PYRAZOLE DERIVATIVE, INTERMEDIATE THEREFOR, PROCESSES FOR PRODUCING THESE, AND HERBICIDE CONTAINING THESE AS ACTIVE INGREDIENT | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2010-06-17 | — | — | US | disclosed |
| US-7700786-B2 | Pyrazole derivative, intermediate therefor, processes for producing these, and herbicide containing these as active ingredient | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20050070441-A1 | Pyrazole derivative, intermediate therefor, processes for producing these, and herbicide containing these as active ingredient | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2005-03-31 | — | — | US | disclosed |
| EP-1362852-A1 | PYRAZOLE DERIVATIVE, INTERMEDIATE THEREFOR, PROCESSES FOR PRODUCING THESE, AND HERBICIDE CONTAINING THESE AS ACTIVE INGREDIENT | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152443-A1 | PYRAZOLE DERIVATIVE, INTERMEDIATE THEREFOR, PROCESSES FOR PRODUCING THESE, AND HERBICIDE CONTAINING THESE AS ACTIVE INGREDIENT | CYP51A1, CYP4F11, WEE1 | THRB 2787/4885THRA 3035/4885SMN1; SMN2 4843/4885 |
| US-20050070441-A1 | Pyrazole derivative, intermediate therefor, processes for producing these, and herbicide containing these as active ingredient | CYP51A1, CYP4F11, WEE1 | THRB 2787/4885THRA 3035/4885SMN1; SMN2 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.